


*Nurse Practitioners, Physician Assistants,  
and Certified Nurse-Midwives: A Policy  
Analysis*

December 1986

NTIS order #PB87-177465



Recommended Citation:

U.S. Congress, Office of Technology Assessment, *Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis* (Health Technology Case Study 37), OTA-HCS-37 (Washington, DC: U.S. Government Printing Office, December 1986) .

Library of Congress Catalog Card Number 85-600596

For sale by the Superintendent of Documents  
U.S. Government Printing Office, Washington, DC 20402

# Preface

*Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis* is Case Study 37 in OTA's Health Technology Case Study Series. This case study has been prepared in response to a request by the Senate Committee on Appropriations.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA's overall project on *The Implications of Cost-Effectiveness Analysis of Medical Technology*. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

- examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);
- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e. g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies are either prepared by OTA staff, commissioned by OTA and performed under contract by experts (generally in academia), or written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, comments are provided to authors, along with OTA's suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least **30** reviewers, and sometimes by 80 or more outside reviewers. These individuals may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA's concern with each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

# Health Technology Case Study Series<sup>a</sup>

Case Study Series No.	Case study title; author(s); OTA Publication number <sup>b</sup>	Case Study Series No.	Case study title; author(s); OTA publication number <sup>b</sup>
1	Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1)) <sup>c</sup>	19	Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19)) <sup>e</sup>
2	The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning; Judith L. Wagner (OTA-BP-H-9(2))	20	Mandatory Passive Restraint Systems in Automobiles: Issues and Evidence; Kenneth E. Warner (OTA-BP-H-15(20)) <sup>f</sup>
3	Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3))	21	Selected Telecommunications Devices for Hearing-Impaired Persons; Virginia W. Stern and Martha Ross Redden (OTA-BP-H-16(21)) <sup>g</sup>
4	Cost Effectiveness of Automated Multichannel Chemistry Analyzers; Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4))	22	The Effectiveness and Costs of Alcoholism Treatment; Leonard Saxe, Denise Dougherty, Katharine Esty, and Michelle Fine (OTA-HCS-22)
5	Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5))	23	The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology Assessment) (OTA-HCS-23)
6	The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6))	24	Variation in Length of Hospital Stay: Their Relationship to Health Outcomes; Mark R. Chassin (OTA-HCS-24)
7	Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7))	25	Technology and Learning Disabilities; Candis Cousins and Leonard Duhl (OTA-HCS-25)
8	The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8))	26	Assistive Devices for Severe Speech Impairments; Judith Randal (Office of Technology Assessment) (OTA-HCS-26)
9	The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9))	27	Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis; Earl P. Steinberg and Alan Cohen (OTA-HCS-27)
10	The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10))	28	Intensive Care Units (ICUs): Clinical Outcomes, Costs, and Decisionmaking; Robert A. Berenson (OTA-HCS-28)
11	Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11))	29	The Boston Elbow; Sandra J. Tanenbaum (OTA-HCS-29)
12	Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12))	30	The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-HCS-30)
13	Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13))	31	The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schiffrin and William J. Rich (OTA-HCS-31)
14	Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14))	32	The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32)
15	Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))	33	Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33)
16	The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16))	34	The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFries, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34)
17	Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17))	35	The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35)
18	The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) <sup>d</sup>	36	Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36)
		37	Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)

<sup>a</sup>Available for sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC, 20402, and by the National Technical Information Service, 5285 Port Royal Rd., Springfield, VA, 22161. Call OTA's Publishing Office (224-8996) for availability and ordering information.

<sup>b</sup>Original publication numbers appear in parentheses.

<sup>c</sup>The first 17 cases in the series were 17 separately issued cases in Background Paper #2: *Case Studies of Medical Technologies*, prepared in conjunction with OTA's August 1980 report *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>d</sup>Background paper #3 to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>e</sup>Background paper #s to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

<sup>f</sup>Background paper #1 to OTA's May 1982 report *Technology and Handicapped People*.

<sup>g</sup>Background paper #2 to *Technology and Handicapped People*.

**OTA Project Staff for Case Study #37**  
**Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives:**  
**A Policy Analysis**

Roger C. Herdman, *Assistant Director, OTA*  
*Health and Life Sciences Division*

Clyde J. Behney, *Health Program Manager*

Gloria Ruby, *Project Director*

Steven Sisskind, *Research Assistant*"

Virginia Cwalina, *Administrative Assistant*

Diann G. Hohenthauer, *F. C. Specialist*

Carol A. Guntow, *Secretary/Word Processor Specialist*

*Principal Contractor*

Edward G. Brooks, University of North Carolina, Chapel Hill, NC

*Contractors*

Louis P. Garrison, The Project Hope Health Sciences Education Center, Millwood, VA

Anne Meadows, Washington, DC (Editing)

---

\*From July to October 1986.

# **Advisory Panel—Nurse Practitioners, Physician Assistants, and Certified Nurse= Midwives: A Policy Analysis**

Rosemary Stevens, *Chair*  
Department of History and the Sociology of Science  
University of Pennsylvania, Philadelphia, PA

Walter H. Caulfield  
Kaiser Permanence  
Oakland, CA

Philip D. Cleveland  
Family Medicine Spokane  
Spokane, WA

Lynn Etheredge  
Health Policy Consultant  
Washington, DC

Willis Goldbeck  
Washington Business Group on Health  
Washington, DC

Sandra Greene  
Health Economics Research  
Blue Cross/Blue Shield of North Carolina  
Durham, NC

Hurdis Griffith  
Robert Wood Johnson Fellow  
Institute of Medicine  
National Academy of Sciences  
Washington, DC

Charles G. Huntington  
Hermon Medical Group  
Hermon, NY

Lauren LeRoy  
Physician Payment Review Commission  
Washington, DC

Kathy Lohr  
The Rand Corp.  
Washington, DC

Ruth Lubic  
Maternity Center Association  
New York, NY

Michael R. Pollard  
Office of Policy Analysis  
Pharmaceutical Manufacturers' Association  
Washington, DC

Patricia A. Prescott  
School of Nursing  
University of Maryland  
Baltimore, MD

Judith Rooks  
Consultant  
Portland, OR

George M. Ryan  
Department of Obstetrics and Gynecology  
College of Medicine  
University of Tennessee  
Memphis, TN

Richard M. Scheffler  
Health Policy and Administration Program  
School of Public Health  
University of California  
Berkeley, CA

Henry M. Seidel  
School of Medicine  
The Johns Hopkins University  
Baltimore, MD

Gerry Shea  
Health Care Division  
Service Employees International Union  
Washington, DC

Barbara Warden  
National Consumers' League  
Washington, DC

Ivan Williams  
Kellogg Center  
Montreal General Hospital  
Montreal, Quebec

NOTE: OTA appreciates and is grateful for the valuable assistance and thoughtful critiques provided by the advisory panel members. The panel does not, however, necessarily approve, disapprove, or endorse this report. OTA assumes full responsibility for the report and the accuracy of its contents,